Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHG6 | ISIN: CA59935V1076 | Ticker-Symbol:
NASDAQ
01.11.24
18:35 Uhr
1,430 US-Dollar
-0,020
-1,38 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MILESTONE PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MILESTONE PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur MILESTONE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.10.Milestone Pharmaceuticals maintains Buy rating from TD Cowen2
14.10.Wainwright maintains Buy rating on Milestone Pharma stock1
06.09.Milestone Pharmaceuticals Inc.: Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China89MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...
► Artikel lesen
04.09.Milestone Pharmaceuticals welcomes new board member Joseph Papa1
04.09.Milestone Pharmaceuticals Inc. - 8-K, Current Report1
04.09.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors1
09.08.Milestone Pharmaceuticals GAAP EPS of -$0.141
09.08.Milestone Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary1
08.08.Milestone Pharmaceuticals Inc. - 8-K, Current Report1
08.08.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update80- NDA for CARDAMYST in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 - Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 - Stuart Duty and Andrew Saik Appointed...
► Artikel lesen
08.08.Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report1
15.07.Milestone Pharmaceuticals Inc. - 8-K, Current Report1
12.06.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals to Host KOL Event for Investors "Learnings from the Field: Expert Perspectives on PSVT in the Community Setting" on June 20, 20241
31.05.Milestone Pharmaceuticals Inc.: Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference1
29.05.Milestone Pharmaceuticals Inc. - 8-K, Current Report-
29.05.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST208MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative...
► Artikel lesen
13.05.Milestone Pharmaceuticals GAAP EPS of -$0.21 beats by $0.051
13.05.Milestone Pharmaceuticals Inc. - 8-K, Current Report-
13.05.Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update165- NDA for etripamil in PSVT resubmitted in 1Q 2024- Cash resources as of March 31, 2024 expected to fund operations into 2026- Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR...
► Artikel lesen
13.05.Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report1
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1